Quince Therapeutics Inc
QNCX
NASDAQ
Biotechnology
$34.04
USD
+1.63 (+5.03%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $33.61M
Volume 25.9K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-33.04M
TTM
+45.6%
YoY
Operating Cash Flow
$-37.53M
TTM
-22.6%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 4.8 | 3.3 | 3.3 | 3.6 | 4.3 |
Other Operating Expenses | 1.9 | 0.5 | 2.1 | 3.1 | 3.5 |
Total Operating Expenses | 14.9 | 10.4 | 13.4 | 19.4 | 14.6 |
Operating Income | -14.9 | -10.4 | -13.4 | -19.4 | -14.6 |
EBITDA | -12.9 | -10.4 | -11.3 | -23.8 | -11.1 |
Other Income / Expense | -0.5 | -5.9 | -0.4 | -17.2 | 45.0 |
Total Other Income / Expense | -0.1 | -5.6 | -0.1 | -17.0 | 45.2 |
Income Before Income Taxes | -15.0 | -16.0 | -13.5 | -36.3 | 30.6 |
Income Taxes | 0.0 | 0.1 | -0.0 | 3.1 | -5.3 |
Net Income | -15.0 | -16.0 | -13.4 | -39.5 | 35.9 |
Consolidated Net Income / Loss | -15.0 | -16.0 | -13.4 | -39.5 | 35.9 |
Net Income Attributable to Common Shareholders | -15.0 | -16.0 | -13.4 | -39.5 | 32.8 |
Basic EPS | -$68.40 | -$68.00 | -$50.00 | -$141.40 | $72.00 |
Diluted EPS | -$68.40 | -$68.00 | -$50.00 | -$141.40 | $57.60 |
Basic Shares Outstanding | 0.2M | 0.2M | 0.3M | 0.3M | 0.5M |
Diluted Shares Outstanding | 0.2M | 0.2M | 0.3M | 0.3M | 0.5M |